Kevin M. Waters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kevin M. Waters has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Brent K. Larson
Department of Pathology and Laboratory Medicine Cedars‐Sinai Medical Center Los Angeles California USA
10 shared publications - Jun Gong
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
8 shared publications - Maha Guindi
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
7 shared publications - Danielle A. Hutchings
Department of Pathology and Laboratory Medicine Cedars‐Sinai Medical Center Los Angeles California USA
5 shared publications - Alexandra Gangi
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, USA
4 shared publications Maha Guindi
Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
4 shared publications
Latest Publications
- 3 November 2026
- Published by Wiley in Histopathology
Small neuroendocrine proliferations in columnar mucosa at or near the gastroesophageal junction: a finding potentially related to proton pump inhibitor use and/or gastroesophageal reflux disease
Aims: Neuroendocrine proliferations have been described in gastrointestinal (GI) mucosa associated with chemoradiation and inflammatory bowel disease (IBD) and can also be seen in gastric mucosa in hypergastrinemic conditions. We have encountered small clusters of neuroendocrine cells in the lamina propria, designated herein as neuroendocrine micronodules (NMs), in biopsies taken at and around the gastroesophageal junction (GEJ) in patients without histories of chemoradiation, IBD or autoimmune metaplastic atrophic gastritis (AMAG) and sought to further characterize their clinicopathological features. Methods: Nine patients with NMs were identified during routine signout. An additional 66 consecutive patients with GEJ biopsies containing ≥1 fragment of columnar mucosa were prospectively evaluated. NMs were identified on haematoxylin and eosin staining and confirmed with chromogranin A immunohistochemistry. Results: NMs were identified in 8% (5/66) of GEJ biopsies in the prospective cohort. Of the 14 total patients with NMs, the median age was 51 years (range 25–78 years) with slight male predominance (1.7:1). 79% reported proton pump inhibitor (PPI) use, 71% had gastroesophageal reflux disease (GERD) and 36% had hiatal hernia. None had IBD, chemoradiation or prior neuroendocrine neoplasia. Associated histological findings included pancreatic metaplasia in 57%, intestinal metaplasia in 7% and linear neuroendocrine cell hyperplasia in 64%. Twelve patients had concurrently sampled oxyntic mucosa and all lacked evidence of AMAG. Conclusions: NMs at the GEJ can be found in up to 8% of unselected biopsies and may occur in patients without AMAG. Possible aetiologies include PPI‐associated ECL hyperplasia and/or GERD‐mediated injury; however, definitive characterization requires further studies.
- 3 November 2026
- Published by Wiley in Histopathology
Small neuroendocrine proliferations in columnar mucosa at or near the gastroesophageal junction: a finding potentially related to proton pump inhibitor use and/or gastroesophageal reflux disease
Aims: Neuroendocrine proliferations have been described in gastrointestinal (GI) mucosa associated with chemoradiation and inflammatory bowel disease (IBD) and can also be seen in gastric mucosa in hypergastrinemic conditions. We have encountered small clusters of neuroendocrine cells in the lamina propria, designated herein as neuroendocrine micronodules (NMs), in biopsies taken at and around the gastroesophageal junction (GEJ) in patients without histories of chemoradiation, IBD or autoimmune metaplastic atrophic gastritis (AMAG) and sought to further characterize their clinicopathological features. Methods: Nine patients with NMs were identified during routine signout. An additional 66 consecutive patients with GEJ biopsies containing ≥1 fragment of columnar mucosa were prospectively evaluated. NMs were identified on haematoxylin and eosin staining and confirmed with chromogranin A immunohistochemistry. Results: NMs were identified in 8% (5/66) of GEJ biopsies in the prospective cohort. Of the 14 total patients with NMs, the median age was 51 years (range 25–78 years) with slight male predominance (1.7:1). 79% reported proton pump inhibitor (PPI) use, 71% had gastroesophageal reflux disease (GERD) and 36% had hiatal hernia. None had IBD, chemoradiation or prior neuroendocrine neoplasia. Associated histological findings included pancreatic metaplasia in 57%, intestinal metaplasia in 7% and linear neuroendocrine cell hyperplasia in 64%. Twelve patients had concurrently sampled oxyntic mucosa and all lacked evidence of AMAG. Conclusions: NMs at the GEJ can be found in up to 8% of unselected biopsies and may occur in patients without AMAG. Possible aetiologies include PPI‐associated ECL hyperplasia and/or GERD‐mediated injury; however, definitive characterization requires further studies.
- 24 July 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (10) , 1195-1204
Next-Generation Sequencing of Multivergent Morphologies in Colorectal Carcinomas Identifies Unique Targetable Alterations
Typically, colorectal carcinoma (CRC) is morphologically relatively homogeneous. Uncommon morphologic patterns may be enriched for rare molecular drivers. This study examined the clinicopathologic characteristics of CRC with multivergent morphology (defined as 2 discrete nonconventional morphologic cytoarchitectural patterns) and whether potentially targetable molecular alterations could be identified by interrogating 2 distinct morphologic areas. Evaluation of representative sections from 213 consecutive CRC resections identified 11 with multivergent morphology. Next-generation sequencing (NGS) was performed on 2 morphologically discrete areas from multivergent cases. Compared with the remaining 202 CRCs, multivergent CRCs were larger (mean: 6.4 vs. 4.4 cm; P =0.038), had a higher T stage (100% vs. 78.2% ≥T3; P =5.0×10 −4 ), a higher N stage (90.9% vs. 42.1% ≥N1, P =7.0×10 −4 ), and more frequently had distant metastasis (36.4% vs. 10.9%; P =0.041). Multivergent CRCs were more likely to be mismatch repair (MMR)-deficient (45.5% vs. 15.8%; P =0.034) and to have an atypical MMR pattern (27.3% vs. 0.5%; P =1.7×10 −7 ). Both areas of multivergent CRC often harbored molecular alterations associated with eligibility for Food and Drug Administration (FDA)-approved therapies (63.6%; 7/11) and clinical trials (72.7%; 8/11). Not uncommonly, a molecular alteration associated with eligibility for FDA-approved therapy (45.5%; 5/11) and clinical trials (72.7%; 8/11) was isolated to only one of the sequenced areas. Multivergent CRC is rare but associated with targetable molecular alterations. NGS of multiple areas with different morphologies may help identify potential therapeutic targets. While most cases have recognizable driver alterations, the less common, targetable alterations identified in these cases could open additional trial options for salvage therapy.
- 24 July 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (10) , 1195-1204
Next-Generation Sequencing of Multivergent Morphologies in Colorectal Carcinomas Identifies Unique Targetable Alterations
Typically, colorectal carcinoma (CRC) is morphologically relatively homogeneous. Uncommon morphologic patterns may be enriched for rare molecular drivers. This study examined the clinicopathologic characteristics of CRC with multivergent morphology (defined as 2 discrete nonconventional morphologic cytoarchitectural patterns) and whether potentially targetable molecular alterations could be identified by interrogating 2 distinct morphologic areas. Evaluation of representative sections from 213 consecutive CRC resections identified 11 with multivergent morphology. Next-generation sequencing (NGS) was performed on 2 morphologically discrete areas from multivergent cases. Compared with the remaining 202 CRCs, multivergent CRCs were larger (mean: 6.4 vs. 4.4 cm; P =0.038), had a higher T stage (100% vs. 78.2% ≥T3; P =5.0×10 −4 ), a higher N stage (90.9% vs. 42.1% ≥N1, P =7.0×10 −4 ), and more frequently had distant metastasis (36.4% vs. 10.9%; P =0.041). Multivergent CRCs were more likely to be mismatch repair (MMR)-deficient (45.5% vs. 15.8%; P =0.034) and to have an atypical MMR pattern (27.3% vs. 0.5%; P =1.7×10 −7 ). Both areas of multivergent CRC often harbored molecular alterations associated with eligibility for Food and Drug Administration (FDA)-approved therapies (63.6%; 7/11) and clinical trials (72.7%; 8/11). Not uncommonly, a molecular alteration associated with eligibility for FDA-approved therapy (45.5%; 5/11) and clinical trials (72.7%; 8/11) was isolated to only one of the sequenced areas. Multivergent CRC is rare but associated with targetable molecular alterations. NGS of multiple areas with different morphologies may help identify potential therapeutic targets. While most cases have recognizable driver alterations, the less common, targetable alterations identified in these cases could open additional trial options for salvage therapy.
- 1 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 491-493
Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening
Recently, stool- and blood-based cancer screening kits have been approved in clinical practice as convenient and noninvasive methods for colon cancer screening. One such test in long-standing practice has included the fecal immunochemical test (FIT), wherein home-based testing has rendered it a convenient initial assay to complement screening colonoscopy, despite limitations in diagnostic performance. In a recent original study published in the journal by Nguyen and colleagues, the feasibility and performance of combining FIT with circulating tumor cell (CTC) enumeration for predicting colorectal neoplasia and the risk of developing colorectal cancer were described. In this commentary, we highlight the potential of this combination as a novel colorectal cancer screening technique. The introduction of CTC as a potential colorectal cancer screening assay is timely, given the emergence of liquid biopsies that hold promise in their ability to detect a multitude of cancer-specific signals, from the detection of minimal residual disease to the detection of molecular alterations for precision therapies in oncology. We place the importance of their results in the context of the evolving landscape of stool- and blood-based colorectal cancer screening tests involving multitarget fecal DNA and cell-free DNA assays. See related article by Nguyen et al., Cancer Epidemiol Biomarkers Prev 2026;35:79–87.
- 1 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 491-493
Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening
Recently, stool- and blood-based cancer screening kits have been approved in clinical practice as convenient and noninvasive methods for colon cancer screening. One such test in long-standing practice has included the fecal immunochemical test (FIT), wherein home-based testing has rendered it a convenient initial assay to complement screening colonoscopy, despite limitations in diagnostic performance. In a recent original study published in the journal by Nguyen and colleagues, the feasibility and performance of combining FIT with circulating tumor cell (CTC) enumeration for predicting colorectal neoplasia and the risk of developing colorectal cancer were described. In this commentary, we highlight the potential of this combination as a novel colorectal cancer screening technique. The introduction of CTC as a potential colorectal cancer screening assay is timely, given the emergence of liquid biopsies that hold promise in their ability to detect a multitude of cancer-specific signals, from the detection of minimal residual disease to the detection of molecular alterations for precision therapies in oncology. We place the importance of their results in the context of the evolving landscape of stool- and blood-based colorectal cancer screening tests involving multitarget fecal DNA and cell-free DNA assays. See related article by Nguyen et al., Cancer Epidemiol Biomarkers Prev 2026;35:79–87.
- 3 March 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (3)
Enhanced detection of high-risk human papillomavirus by in situ hybridization with expansion from 7 to 18 genotypes in anal biopsies
Objectives: High-risk human papillomavirus (HPV) plays a central role in the pathogenesis of anal high-grade squamous intraepithelial lesions (HSILs). In situ hybridization (ISH) is commonly used for high-risk HPV detection in surgical specimens. Recently, ISH panels with expanded HPV genotype cocktails have become available. This study evaluated the detection rate of an expanded ISH probe cocktail targeting 18 high-risk HPV genotypes (HR18) compared with a 7-HPV genotype panel (HR7) in anal tissue microarray samples. Methods: A retrospective study was performed on 245 patients with anal biopsy samples collected from 2017 to 2023 at a tertiary-care medical center. Tissue microarrays were constructed with 1 to 3 cores per case. In situ hybridization was performed with an HR18 probe for comparison with the reported HR7 result. The detection rate of high-risk HPV was assessed. Results: Among 55 patients with HSIL, HR18 demonstrated a positivity rate of 93% (51/55) compared with 73% (40/55) for HR7 (P = 2.6 × 10−3). The HR18 panel detected high-risk HPV in 3 patients with histologically low-grade and 1 previously ungraded SIL. No high-risk HPV was detected in patients without SIL by HR18. Conclusions: Expansion of the ISH panel from 7 to 18 genotypes improved detection for high-risk HPV in anal HSIL and identified high-risk HPV in additional patients without HSIL.
- 3 March 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (3)
Enhanced detection of high-risk human papillomavirus by in situ hybridization with expansion from 7 to 18 genotypes in anal biopsies
Objectives: High-risk human papillomavirus (HPV) plays a central role in the pathogenesis of anal high-grade squamous intraepithelial lesions (HSILs). In situ hybridization (ISH) is commonly used for high-risk HPV detection in surgical specimens. Recently, ISH panels with expanded HPV genotype cocktails have become available. This study evaluated the detection rate of an expanded ISH probe cocktail targeting 18 high-risk HPV genotypes (HR18) compared with a 7-HPV genotype panel (HR7) in anal tissue microarray samples. Methods: A retrospective study was performed on 245 patients with anal biopsy samples collected from 2017 to 2023 at a tertiary-care medical center. Tissue microarrays were constructed with 1 to 3 cores per case. In situ hybridization was performed with an HR18 probe for comparison with the reported HR7 result. The detection rate of high-risk HPV was assessed. Results: Among 55 patients with HSIL, HR18 demonstrated a positivity rate of 93% (51/55) compared with 73% (40/55) for HR7 (P = 2.6 × 10−3). The HR18 panel detected high-risk HPV in 3 patients with histologically low-grade and 1 previously ungraded SIL. No high-risk HPV was detected in patients without SIL by HR18. Conclusions: Expansion of the ISH panel from 7 to 18 genotypes improved detection for high-risk HPV in anal HSIL and identified high-risk HPV in additional patients without HSIL.
- 6 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (3) , 729-735
Pulmonary immunohistochemical markers may be positive in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis
Background: Autoimmune metaplastic atrophic gastritis (AMAG) causes pulmonary trans‐differentiation of the gastric mucosa and is known to increase the risk of developing gastric adenocarcinoma. AMAG‐associated gastric adenocarcinomas were examined for immunoreactivity for TTF‐1 and Napsin A. Design: Eighteen AMAG‐associated gastric adenocarcinomas and 36 non‐AMAG‐associated gastric adenocarcinomas were stained for TTF‐1 (clones SP141 and 8G7G3/1) and Napsin A (clone 1P64) by immunohistochemistry. AMAG stage and staining patterns were characterized. Results: The AMAG group was older (mean age 74 vs. 65 years) and was not significantly different with regard to sex or tumour differentiation. Zero (0%) AMAG cases were classified as early phase, four (22%) as florid phase and 14 (78%) as end stage. AMAG‐associated adenocarcinomas showed more frequent TTF‐1 immunoreactivity compared to control adenocarcinomas in both clone SP141 (39% vs. 11%; P = 0.04) and 8G7G3/1 (22% vs. 6%; P = 0.17). AMAG‐associated adenocarcinomas showed more frequent Napsin A immunoreactivity compared to control adenocarcinomas (28% vs. 0%; P < 0.01). Immunoreactivity in AMAG‐associated adenocarcinomas was patchy, ranging from 1% to 20% of tumour cells staining positive (1+ to 3+ intensity). In the AMAG cases with background gastric mucosa (n = 14), the background showed TTF‐1 positive foci in seven (50%) cases (both clones) versus one (3%; clone SP141) to two (6%; clone 8G7G3/1) of 33 controls ( P < 0.01) and Napsin A positive foci in five (36%) cases versus zero (0%) controls ( P < 0.01). Staining in background mucosa was also patchy, involving 1%–10% of gastric glands without intestinal metaplasia. Conclusion: TTF‐1 and Napsin A immunoreactivity was present in the background gastric mucosa almost exclusively in the AMAG‐associated cases. This immunoreactivity is also present in AMAG‐associated adenocarcinomas more commonly than non‐AMAG‐associated adenocarcinomas. This knowledge may aid pathologists in avoiding the pitfall of diagnosing metastatic lung cancer, as the expression is patchy and may also be seen in atrophic background mucosa.
- 6 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (3) , 729-735
Pulmonary immunohistochemical markers may be positive in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis
Background: Autoimmune metaplastic atrophic gastritis (AMAG) causes pulmonary trans‐differentiation of the gastric mucosa and is known to increase the risk of developing gastric adenocarcinoma. AMAG‐associated gastric adenocarcinomas were examined for immunoreactivity for TTF‐1 and Napsin A. Design: Eighteen AMAG‐associated gastric adenocarcinomas and 36 non‐AMAG‐associated gastric adenocarcinomas were stained for TTF‐1 (clones SP141 and 8G7G3/1) and Napsin A (clone 1P64) by immunohistochemistry. AMAG stage and staining patterns were characterized. Results: The AMAG group was older (mean age 74 vs. 65 years) and was not significantly different with regard to sex or tumour differentiation. Zero (0%) AMAG cases were classified as early phase, four (22%) as florid phase and 14 (78%) as end stage. AMAG‐associated adenocarcinomas showed more frequent TTF‐1 immunoreactivity compared to control adenocarcinomas in both clone SP141 (39% vs. 11%; P = 0.04) and 8G7G3/1 (22% vs. 6%; P = 0.17). AMAG‐associated adenocarcinomas showed more frequent Napsin A immunoreactivity compared to control adenocarcinomas (28% vs. 0%; P < 0.01). Immunoreactivity in AMAG‐associated adenocarcinomas was patchy, ranging from 1% to 20% of tumour cells staining positive (1+ to 3+ intensity). In the AMAG cases with background gastric mucosa (n = 14), the background showed TTF‐1 positive foci in seven (50%) cases (both clones) versus one (3%; clone SP141) to two (6%; clone 8G7G3/1) of 33 controls ( P < 0.01) and Napsin A positive foci in five (36%) cases versus zero (0%) controls ( P < 0.01). Staining in background mucosa was also patchy, involving 1%–10% of gastric glands without intestinal metaplasia. Conclusion: TTF‐1 and Napsin A immunoreactivity was present in the background gastric mucosa almost exclusively in the AMAG‐associated cases. This immunoreactivity is also present in AMAG‐associated adenocarcinomas more commonly than non‐AMAG‐associated adenocarcinomas. This knowledge may aid pathologists in avoiding the pitfall of diagnosing metastatic lung cancer, as the expression is patchy and may also be seen in atrophic background mucosa.
- 22 November 2024
- Published by Elsevier in Human Pathology
- Vol. 154, 105694
Clinicopathologic findings in a cohort of metastases to the stomach
- 22 November 2024
- Published by Elsevier in Human Pathology
- Vol. 154, 105694
Clinicopathologic findings in a cohort of metastases to the stomach
- 3 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 890-904
Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001–2019 US Cancer Statistics Databases
INTRODUCTION: Upper gastrointestinal (UGI) cancers, comprising malignancies of the esophagus, stomach, duodenum, pancreas, liver, biliary tract, and gallbladder, are the second leading cause of cancer-related mortality in the United States and are associated with significant comorbidities. Recent studies show a disproportionate rise in pancreatic and stomach cancer among young adults. This study aims to use a nationwide, population-based cohort to (i) evaluate the trend of all UGI cancer as an aggregate and (ii) examine the role of demographics, histology, and tumor stage in UGI cancer incidence among young adults. METHODS: Individuals diagnosed with UGI cancer in the United States from 2001 to 2019 were identified and obtained from the Surveillance, Epidemiology, and End Results—National Program of Cancer Registries database. The primary outcomes were incidence rates of UGI cancer (calculated per 100,000, age-adjusted to the year 2000 US population), stratified by sex and age (< 55 years for young adults and ≥ 55 years for older adults). Trends, annual percentage change, and average annual percentage change were calculated using the parametric method. Sensitivity analysis was performed according to primary site and histology; further analysis examining race and cancer stage was performed in the young adult subgroup. RESULTS: A total of 2,333,161 patients with UGI cancer were identified. Most cases were male, and 14.3% were < 55 years of age. Incidence of UGI cancer increased most in women younger than 55 years, driven primarily by pancreatic and stomach cancers, as well as neuroendocrine tumor and gastrointestinal stromal tumor histology. African American race and localized tumors and malignancy with distant spread are also contributing to the disparate increase among young women. UGI mortality rates have not changed significantly in young adults. DISCUSSION: The overall incidence rate of upper gastrointestinal cancer is increasing significantly in young women compared with men. Increased endoscopic procedures and disparate exposure to risk factors are likely contributing to these trends.
- 3 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 890-904
Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001–2019 US Cancer Statistics Databases
INTRODUCTION: Upper gastrointestinal (UGI) cancers, comprising malignancies of the esophagus, stomach, duodenum, pancreas, liver, biliary tract, and gallbladder, are the second leading cause of cancer-related mortality in the United States and are associated with significant comorbidities. Recent studies show a disproportionate rise in pancreatic and stomach cancer among young adults. This study aims to use a nationwide, population-based cohort to (i) evaluate the trend of all UGI cancer as an aggregate and (ii) examine the role of demographics, histology, and tumor stage in UGI cancer incidence among young adults. METHODS: Individuals diagnosed with UGI cancer in the United States from 2001 to 2019 were identified and obtained from the Surveillance, Epidemiology, and End Results—National Program of Cancer Registries database. The primary outcomes were incidence rates of UGI cancer (calculated per 100,000, age-adjusted to the year 2000 US population), stratified by sex and age (< 55 years for young adults and ≥ 55 years for older adults). Trends, annual percentage change, and average annual percentage change were calculated using the parametric method. Sensitivity analysis was performed according to primary site and histology; further analysis examining race and cancer stage was performed in the young adult subgroup. RESULTS: A total of 2,333,161 patients with UGI cancer were identified. Most cases were male, and 14.3% were < 55 years of age. Incidence of UGI cancer increased most in women younger than 55 years, driven primarily by pancreatic and stomach cancers, as well as neuroendocrine tumor and gastrointestinal stromal tumor histology. African American race and localized tumors and malignancy with distant spread are also contributing to the disparate increase among young women. UGI mortality rates have not changed significantly in young adults. DISCUSSION: The overall incidence rate of upper gastrointestinal cancer is increasing significantly in young women compared with men. Increased endoscopic procedures and disparate exposure to risk factors are likely contributing to these trends.
- 16 July 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (10) , 100567
Analysis of the Application of Professional Society Screening Guidelines for Colorectal Polyposis Syndromes at a Single Institution
- 16 July 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 37 (10) , 100567
Analysis of the Application of Professional Society Screening Guidelines for Colorectal Polyposis Syndromes at a Single Institution
- 12 February 2024
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 162 (1) , 41-50
5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms
Adenocarcinomas of the biliary tract frequently present diagnostic challenges because of their histologic overlap with benign and preinvasive lesions. The molecular profiles of biliary adenocarcinomas vary by anatomical location. Variations in IDH1/2, common in intrahepatic cholangiocarcinoma, can lead to defective production of 5-hydroxymethylcytosine (5-hmC). Limited ancillary studies are available for biliary adenocarcinomas, and loss of 5-hmC staining could serve as a helpful ancillary diagnostic tool for biliary tract malignancies. We evaluated 93 cases—20 benign biliary lesions, 15 preinvasive biliary neoplasms, 46 invasive biliary carcinomas, and 12 pancreatic adenocarcinomas—for 5-hmC staining. Preoperative biopsies from 16 cases of biliary carcinoma were also stained. Sixteen nonneoplastic/reactive bile duct biopsies served as controls. Loss of 5-hmC was seen in 41 of 46 (89.1%) biliary malignancies vs 0 of 20 benign tumors (P < .001), for a sensitivity and specificity of 89.1% and 100%, respectively. Intrahepatic cholangiocarcinoma showed loss of 5-hmC in 11 of 13 (84.6%) cases, similar to the 30 of 33 (90.9%) cases in other biliary adenocarcinomas (P = .61). Similarly, 5-hmC loss was more frequent in distal bile duct adenocarcinomas than in pancreatic ductal adenocarcinomas, at 15 of 17 (88.2%) vs 4 of 12 (33.3%), respectively (P = .0045). There was no difference in the frequency of 5-hmC loss in patients that received neoadjuvant therapy vs those who did not (90.9% vs 88.6%, P > .99). 5-hmC immunohistochemistry in preoperative biopsies was concordant with the resection specimen in 81.3% (13/16) of cases. Loss of 5-hmC is not unique to intrahepatic cholangiocarcinoma among biliary carcinomas, but is a useful diagnostic marker differentiating malignancies of the biliary tree from benign mimics.
- 12 February 2024
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 162 (1) , 41-50
5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms
Adenocarcinomas of the biliary tract frequently present diagnostic challenges because of their histologic overlap with benign and preinvasive lesions. The molecular profiles of biliary adenocarcinomas vary by anatomical location. Variations in IDH1/2, common in intrahepatic cholangiocarcinoma, can lead to defective production of 5-hydroxymethylcytosine (5-hmC). Limited ancillary studies are available for biliary adenocarcinomas, and loss of 5-hmC staining could serve as a helpful ancillary diagnostic tool for biliary tract malignancies. We evaluated 93 cases—20 benign biliary lesions, 15 preinvasive biliary neoplasms, 46 invasive biliary carcinomas, and 12 pancreatic adenocarcinomas—for 5-hmC staining. Preoperative biopsies from 16 cases of biliary carcinoma were also stained. Sixteen nonneoplastic/reactive bile duct biopsies served as controls. Loss of 5-hmC was seen in 41 of 46 (89.1%) biliary malignancies vs 0 of 20 benign tumors (P < .001), for a sensitivity and specificity of 89.1% and 100%, respectively. Intrahepatic cholangiocarcinoma showed loss of 5-hmC in 11 of 13 (84.6%) cases, similar to the 30 of 33 (90.9%) cases in other biliary adenocarcinomas (P = .61). Similarly, 5-hmC loss was more frequent in distal bile duct adenocarcinomas than in pancreatic ductal adenocarcinomas, at 15 of 17 (88.2%) vs 4 of 12 (33.3%), respectively (P = .0045). There was no difference in the frequency of 5-hmC loss in patients that received neoadjuvant therapy vs those who did not (90.9% vs 88.6%, P > .99). 5-hmC immunohistochemistry in preoperative biopsies was concordant with the resection specimen in 81.3% (13/16) of cases. Loss of 5-hmC is not unique to intrahepatic cholangiocarcinoma among biliary carcinomas, but is a useful diagnostic marker differentiating malignancies of the biliary tree from benign mimics.
- 8 January 2024
- Published by Wiley in Histopathology
- Vol. 84 (5) , 888-892
Markedly increased duodenal villous surface apoptosis in patients taking pre‐exposure prophylaxis (PrEP) against human immunodeficiency virus
Aims: Pre‐exposure prophylaxis (PrEP) consists of combination antiretroviral therapy and is increasingly utilized to prevent human immunodeficiency virus (HIV) in high‐risk populations. Two index cases noted during routine care showed markedly increased duodenal villous surface apoptosis in patients on PrEP. We sought to examine the prevalence of this finding and identify any clinicopathologic correlations.Methods: Gastrointestinal biopsy specimens from 23 male patients aged 18–40 years taking PrEP and 23 control patients were reviewed. Patients with HIV, inflammatory gastrointestinal diseases, and celiac disease were excluded. Apoptoses were counted on surface epithelium and deep crypts. The highest apoptotic body count per tissue fragment was recorded. Clusters were defined as groups of ≥5 apoptoses. Apoptotic counts between patients taking PrEP and controls were compared using t‐tests.Results: In PrEP patients, the median age was 35 years (range 25–40) and 83% (19/23) were white. The control patients were demographically similar (median age: 32 years [range 23–40]; 70% [16/23] white). Duodenal apoptosis in villous surface epithelium was increased in PrEP patients, with 14/23 (60.9%) patients having ≥10 surface apoptoses compared to 2/23 (8.7%) controls (P = 2.1 × 10−3) and 14/23 (61%) having clusters compared to 3/23 (13%) controls (P = 2.0 × 10−3). There was no significant association between increased surface apoptosis or clusters and clinical symptoms or duration of PrEP use.Conclusion: Markedly increased villous surface apoptosis, particularly in clusters, is often seen in the duodenum of patients taking PrEP. Although the mechanism and significance are unknown, knowledge of this peculiar finding may prevent unnecessary additional testing.
- 8 January 2024
- Published by Wiley in Histopathology
- Vol. 84 (5) , 888-892
Markedly increased duodenal villous surface apoptosis in patients taking pre‐exposure prophylaxis (PrEP) against human immunodeficiency virus
Aims: Pre‐exposure prophylaxis (PrEP) consists of combination antiretroviral therapy and is increasingly utilized to prevent human immunodeficiency virus (HIV) in high‐risk populations. Two index cases noted during routine care showed markedly increased duodenal villous surface apoptosis in patients on PrEP. We sought to examine the prevalence of this finding and identify any clinicopathologic correlations.Methods: Gastrointestinal biopsy specimens from 23 male patients aged 18–40 years taking PrEP and 23 control patients were reviewed. Patients with HIV, inflammatory gastrointestinal diseases, and celiac disease were excluded. Apoptoses were counted on surface epithelium and deep crypts. The highest apoptotic body count per tissue fragment was recorded. Clusters were defined as groups of ≥5 apoptoses. Apoptotic counts between patients taking PrEP and controls were compared using t‐tests.Results: In PrEP patients, the median age was 35 years (range 25–40) and 83% (19/23) were white. The control patients were demographically similar (median age: 32 years [range 23–40]; 70% [16/23] white). Duodenal apoptosis in villous surface epithelium was increased in PrEP patients, with 14/23 (60.9%) patients having ≥10 surface apoptoses compared to 2/23 (8.7%) controls (P = 2.1 × 10−3) and 14/23 (61%) having clusters compared to 3/23 (13%) controls (P = 2.0 × 10−3). There was no significant association between increased surface apoptosis or clusters and clinical symptoms or duration of PrEP use.Conclusion: Markedly increased villous surface apoptosis, particularly in clusters, is often seen in the duodenum of patients taking PrEP. Although the mechanism and significance are unknown, knowledge of this peculiar finding may prevent unnecessary additional testing.